Aribio said on the 23rd that it signed a $230 million (330 billion won) technology transfer contract with U.S. corporations Lestari. It is an export of technology for new drug candidates for kidney and liver diseases. The amount includes an upfront payment and milestones to be paid when clinical trials, approvals and other stages achieve results. Royalties linked to sales after product launch will be paid separately.
Using Aribio's next-generation phosphodiesterase (PDE)-5 inhibitor new drug technology, Lestari can develop and commercialize a treatment program. The company said the contract is separate from the oral Alzheimer's treatment candidate (AR1001).
An Aribio official said it "will offer patients a practical treatment alternative."
※ This article has been translated by AI. Share your feedback here.